Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease
Non-invasive assessment of cACLD & portal hypertension
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his
Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH
Burden of Liver-Related Comorbidities in Cardiovascular Disease
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular
Discover all about NASH, NAFLD PPAR agonists ⟶
NAFLD Pathophysiologic Role of Intrahepatic Vasculature Slides
Dr. Kwanten (Belgium) discusses the role of pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions
How to integrate NASH assessment and management into the care of diabetic patient
Dr. Castera discusses how clinicians can integrate NASH assessment and management into the care of diabetic patients in order to
Cancers and NASH
Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented
The “perfect” NASH biomarker: an unrealistic pursuit?
The rise of obesity and type 2 diabetes during the past 20 years has been accompanied by an increase in their associated multiorgan impairments. Non-alcoholic fatty liver disease (NAFLD) is one such complication. As a complex multisystem disease, it is characterised by fibrosis as well as cross-talk between the liver and extrahepatic organs, thereby heightening the risk of adverse clinical outcomes.
Cardiovascular risk in patients with NAFLD and inflammatory bowel diseases
Metabolic syndrome and its associated conditions (obesity, insulin resistance, and dyslipidemia) are well-characterised risk factors for non-alcoholic fatty liver disease (NAFLD). However, recent studies have noted NAFLD’s increased prevalence in patients with inflammatory bowel diseases (IBD).
Costs of care for non-alcoholic steatohepatitis in the United States: a review
Out of all patients with NAFLD, around 20% develop non-alcoholic steatohepatitis, NASH. This condition is categorised by symptoms such as the progressive fibrosis of the liver, often followed with cirrhosis and liver failure.
Non-invasive tests and their cut-offs for assessing fibrosis: a review
In the general population, there are high prevalence rates of NAFLD, non-alcoholic fatty liver disease. Hence, it is vital to identify the advanced stages of liver fibrosis in these individuals accurately to allow for proper treatment. Non-invasive tests, such as FIB-4 and transient elastography, are valuable tools for identifying patients who require specialist care.
New this week!
NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and
EDITOR OF THE MONTH!
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of …
Latest Research toward the treatment of NASH disease
Knowledge is crucial for healthcare professionals to manage and diagnose patients with NASH and NAFLD. Over the years, we have been increasingly communicating the results achieved by research, showcasing the latest on therapy to diagnosis and management.
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and
HCC Pathogenesis in NASH and the Impact of Fibrosis
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in
NASH Treatment in 2022: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of
UPCOMING NASH EVENTS
AASLD EMERGING TOPIC CONFERENCE
COMMENTED ARTICLES
The “perfect” NASH biomarker: an unrealistic pursuit?
The rise of obesity and type 2 diabetes during the past 20 years has been accompanied by an increase in their associated multiorgan impairments. Non-alcoholic fatty liver disease (NAFLD) is
Cardiovascular risk in patients with NAFLD and inflammatory bowel diseases
Metabolic syndrome and its associated conditions (obesity, insulin resistance, and dyslipidemia) are well-characterised risk factors for non-alcoholic fatty liver disease (NAFLD). However, recent studies have noted NAFLD’s increased prevalence in
CATEGORIES
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Latest articles from PubMed
- Clinical and Liver Enzymes among the Patients with Metabolic Syndrome with or without Non Alcoholic Fatty Liver Disease attending a Tertiary Care Hospital April 1, 2023
- The association between endocrine disrupting chemicals and MAFLD: Evidence from NHANES survey March 31, 2023
- The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial March 31, 2023
- Central sensitivity to free triiodothyronine with MAFLD and its progression to liver fibrosis in euthyroid adults March 31, 2023
- Features of clinical, biochemical, and sonographic parameters in patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease March 31, 2023
- Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis March 31, 2023
- Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials March 30, 2023
- Non-alcoholic fatty liver disease in diabetes mellitus patients on chronic hemodialysis - A case series addressing cardiovascular and mortality risks March 30, 2023
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.